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Abstract: We report a case of a 53-year old patient with symptoms of congestive heart failure in whom a restrictive 
cardiomyopathy and a kappa-chain monoclonal gammopahty were diagnosed. Treatment with eight cycles of Bortezomib, 
a proteasome inhibitor, resulted in a significant regression of myocardial amyloid deposition and a notable clinical and 
hemodynamic improvement. Over the last few years, the management of cardiac amyloidosis has taken advantage of 
many of the advances of the chemotherapeutic regimens, as well as the wider availability of stem cell transplantation. The 
management of cardiac amyloidosis is also expected to evolve and improve with the better understanding of the specific 
mechanisms of amyloidogenesis and myocardial deposition. This will probably make certain molecules targeting specific 
sites in this process, as potentially effective and minimally toxic compared therapy with the currently used ones. In this 
article, we describe one of the first reported cases of cardiac amyloidosis, successfully treated with Bortezomib. We 
describe and discuss the mechanisms of action of Bortezomib and provide a detailed review of cardiac amyloidosis, from 
pathophysiology to diagnosis and treatment.  
CASE PRESENTATION 
  We describe the case of a 53-year old male patient with 
no known cardiac risk factors, who presented to our 
emergency room for a new onset of dyspnea on exertion and 
chest discomfort. His past medical history was unremarkable 
except for a history of bilateral carpal tunnel syndrome, for  
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which he underwent bilateral median nerve decompression 4 
years before this presentation. At that time, he underwent a 
simple median nerve relief surgery with no pathological 
examination. His family history was unremarkable; he 
denied tobacco, alcohol or over-the-counter medications use. 
Clinical examination was significant for crackles over lung 
bases, III/VI systolic ejection murmur over the apex with no 
pericardial knock or rubs heard. There was no palpable 
organomegaly but grade I-II lower extremity edema. His 
neurological examination was unremarkable. His cardiac 
enzymes were negative but BNP was elevated at 1270 pg/ml. 
His chest X-Ray revealed cardiomegaly and mild bilateral 
pulmonary congestion. A 12-leads electrocardiogram (Fig. 1)
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revealed low voltage in the limb leads with non-specific 
inferior and lateral ST-T changes.  
  A transthoracic echocardiography showed a thickened 
interventricular septum and posterior wall at 1.9 cm, high 
normal internal ventricular diastolic and systolic dimensions 
at 5.6 cm and 4.0 cm respectively and moderately enlarged 
left atrium at 5.1 cm. Two-dimensional imaging revealed 
also an increased left ventricular size and mass with a 
“granular sparkling” myocardial appearance. The Left 
ventricle was globally and moderately hypo-kinetic with an 
estimated ejection fraction of 35%. Doppler examination re-
vealed moderate mitral regurgitation. Mitral inflow pattern 
was consistent with restrictive physiology with lack of 
respiratory variation. The right ventricular systolic pressure 
was 40 mmHg. A restrictive cardiomyopahty secondary to a 
systemic amyloidosis was suspected. A left and right heart 
catheterization consistently revealed a mild global 
hypokinesis with an estimated ejection fraction of 40% and a 
2 to 3+ grade mitral regurgitation. Right and left ventricles 
hemodynamic evaluation (Fig. 2) revealed a concordant 
increase and decrease of both pressures with respiration, 
suggestive of a restrictive physiology. It also showed eleva-
ted right chambers pressures with right atrial pressure 
20mmHg, right ventricular pressure of 56/20 mmHg, pul-
monary capillary wedge pressure (PCWP) of 33 mmHg and 
mean pulmonary arterial pressure (MPAP) of 40 mmHg.  
  A bone marrow biopsy showed a medullary plasma-
cytosis (10-15%) and stained positive for amyloid with 
Congo-red staining (Fig. 3). Serum immunofixation electro-
phoresis showed a discrete monoclonal IgG Kappa band and 
a serum kappa-chain concentration of 2,226. Urine protein 
electrophoresis (823 mg of protein collected in 24 h) showed 
a discrete band of Kappa light chain. Myocardial biopsy was 
deferred by the patient. A skeletal survey showed no lytic 
lesions. The diagnosis of kappa-chain systemic amyloidosis 
with cardiac involvement was made based on the simul-
taneous presence of the following findings: the presence of 
monoclonal kappa-chain producing bone marrow plasma 
cells, the electrocardiographic and echocardiographic proof 
of myocardial infiltrative disorder highly suggestive of 
amyloidosis, and the restrictive hemodynamic findings on 
right and left cardiac catheterization. The combination of 
these findings with our patient clinical presentation provided 
a quite convincing explanation for the etiology of his restric-
tive cardiomyopathy, precluding the need for an endomyo-
cardial biopsy.  
Fig. (3). Congo-Red stain done on the patient’s bone marrow 
biopsy, showing focal apple-green fluorescence under polarized 
light, consistent with amyloid deposits.  
  The patient was deemed ineligible for stem cell trans-
plantation. Chemotherapy targeting kappa-chain amyloidosis 
was initiated. Eight cycles of Melphalan and high dose of 
Dexamethasone were administered. After several months of 
therapy, this regimen has failed to improve our patient’s 
performance status, ejection fraction (35%) or reduce ventri-
cular wall thickness. A trial of Thalidomide was initiated but 
ended quickly because of significant intolerance and the 
development of deep venous thrombosis. Bortezomib was 
then started at a dose of 1.3 mg/ m2 for eight cycles over 5 
months. Like other cytotoxic agents traditionally used in the 
treatment of AL amyloidosis, bortezomib is know to target 
neoplastic cells and enhance their apoptosis through different 
mechanisms as detailed later in our review. The end result 
Fig. (2). Right and left ventricular tracing with concordant change in pressures during expiration and inspiration confirming the diagnosis of 
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will be a reduction of the production and burden of amy-
loidogenic proteins, minimizing their deposition in various 
tissues including the myocardium. This regimen was well 
tolerated and no major side effects were observed. After 12 
weeks of treatment, the patient reported a significant impro-
vement in his functional capacity, exercise tolerance, and 
significant improvement of his exertional dyspnea and chest 
discomfort. The clinical improvement correlated with the 
disappearance of monoclonal spikes on serum and urine 
electrophoresis with a significant reduction in serum Kappa 
and Lambda light chains concentration. His follow-up elec-
trocardiogram is shown below (Fig. 4). A follow-up echo-
cardiography showed a significant regression of amyloid 
myocardial infiltration, decreased interventricular septum 
and posterior wall thickness from 1.9 to 1.3 cm, decreased 
left atrial diameter from 5.1 to 4.7 cm, and improvement of 
left ventricular ejection fraction from 35% to 55%. Until last 
seen in his scheduled appointment, the patient remained in 
good status and will continue to follow at our facility.  
CARDIAC AMYLOIDOSIS 
Introduction 
  Amyloidosis refers to heterogeneous diseases, caused by 
protein conformation disorders in which different soluble 
proteins aggregate as extracellular insoluble fibrils in 
different tissues and organs [1]. The disease’s symptoms and 
manifestations are broad and insidious, delaying the dia-
gnosis and often causing significant organ dysfunction 
before a diagnosis is made. Organ dysfunction results from 
both disruption of tissue architecture by amyloid deposits 
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and direct cytotoxic effects of light chains [2]. The prognosis 
is mainly determined by the presence and extent of heart 
involvement as well as the response to therapy [3]. Cardiac 
involvement is a common finding and is the most frequent 
cause of death in Amyloidosis [4]. The incidence of cardiac 
involvement is 50 % in patients with AL (Immunoglobulin 
light chain disease) Amyloidosis. It is however less frequent 
in AA Amyloidosis (serum Amyloid A protein deposition 
disease) and the familial syndromes with 10% and 5% 
respectively. In these setting, it is usually associated with 
milder disease [5]. It accounts for 10% of causes of non-
ischemic cardiomyopathy with significantly high mortality 
rate of up to 50 % [6]. Clinically apparent heart disease is 
present in one third of patients although the heart is virtually 
always involved when studied pathologically [4]. It is 
estimated that 25 % of the myocardial mass is replaced with 
amyloid at the time the patient exhibits symptoms and signs 
of heart failure [6].  
Classification and Diagnosis 
  Acquired systemic amyloidosis occurs in more than 10 
per million person-years in the U.S. population [7] and is 
probably much under diagnosed in the elderly population. 
Systemic AL amyloidosis is the most serious and commonly 
diagnosed form, with 2,000 to 2,500 newly diagnosed cases 
annually in the United States [8]. The classification of 
cardiac amyloidosis is based on the nature of precursor 
protein.  
1)  AL Amyloidosis (Immunoglobulin light chain 
disease): the most common and aggressive form of 
amyloidosis. Its incidence is around 8.9 per million, 
with peak onset around the sixth decade and male to 
female ratio of 3:2 [9, 10]. Theoretically, any organ 
can be infiltrated by light chain. The kidney and the 
heart remain the most common organ involved 
whereas other organs like liver and peripheral and 
autonomic nervous system are much less commonly 
involved. It is estimated that at least two-third of 
patients with AL amyloidosis have more than one 
affected organ when the diagnosis is made [11] and 
less than 5% of patients have clinically isolated heart 
involvement [13]. The light chains are formed by part 
or the whole variable (VL) domain of the 
immunoglobulin [14]. The / chain ratio higher than 
2:1 in AL amyloidosis and may reach 4:1 in cases of 
cardiac involvement [15]. Due to conformational 
changes, monoclonal light chains aggregates into 
amyloid fibrils, leading to their deposition in any 
organ, except brain tissue [11, 16]. The confor-
mational change is the result of a change in the amino 
acid sequence or a proteolysis event, making the light 
chain vulnerable to thermodynamic changes leading 
to self aggregation [2]. Light chain secretion and 
organ infiltration are associated in 80% of cases with 
a benign monoclonal gammopathy [14] but could also 
be secreted by multiple myeloma, lymphomas, and 
macroglobulinaemia. Cardiac involvement is found in 
60 to 90% of patients with AL amyloidosis, up to half 
of cases presenting with advanced symptoms of right 
sided heart failure and echocardio-graphic evidence of 
diastolic dysfunction, reflecting the aggressive nature 
of the disease [9, 14]. The estimated median survival 
is as low as 4 months with most deaths being due to 
refractory congestive heart and arrhythmias [9].  
2)  Systemic AA or secondary amyloidosis is caused   
by the deposition of reactive Amyloid “A” fibrils, 
produced from an underlying inflammatory or neo-
plastic process. While cardiac involvement is usually 
rare and mild, the kidney involvement manifested by 
proteinuria and renal failure is very common [14]. The 
associated organ dysfunction is likely to resolve after 
the treatment of underlying disease [9] and usually 
reflected by a reduction in the SAA concentration and 
results in improved survival [16]. 
3)  Hereditary amyloidosis is caused the deposition of a 
mutant transthyretin protein synthesized by the liver. 
Other less common amyloidogenic proteins include 
apolipoprotein A-I, lysozyme, fibrinogen alpha-chain 
and other rare proteins [14]. An Isoleucine 122 gene 
mutation of TTR DNA is known to be associated 
frequently with a milder degree of cardiac involve-
ment compared with AL amyloidosis [9] and is 
present in 4% of African-Americans, and 23% of 
African-Americans with cardiac amyloidosis have this 
variant [16]. Other manifestations include peripheral 
neuropathy and nephropathy.  
4)  Senile systemic amyloidosis with cardiac involvement 
is seen in 25% of persons older than 80 years. It is 
caused by the deposition of normal transthyretin in 
multiple organs a mainly atrial cardiac tissue [9, 10]. 
It is usually clinically unrecognized until massive 
tissue deposition occurs and leads to heart failure. 
However, an estimated median survival at 75 month 
reflects its milder course and favorable prognosis [9]. 
5)  Hemodialysis-associated amyloidosis occurs with 
chronic hemodialysis and is characterized by the 
deposits of the Beta-2 microglobulin amyloid fibril 
subunit mainly in skeleton and joints and minimal 
myocardial involvement.  
6)  Isolated atrial amyloidosis without systemic involve-
ment is a common finding at autopsy defined as a thin 
endocardial layer. It is commonly seen in elderly 
patients with chronic atrial fibrillation and valvular 
disease and its clinical significance is unknown.  
  The differentiation between these subtypes done based on 
immunohistochemical and genetic testing helps to tailor the 
therapeutic strategy and defines the prognosis. 
Pathophysiology and Clinical Manifestations 
  Cardiac amyloid infiltration affects contractility, electric 
conduction and coronary flow. On autopsy, the most 
common finding is mild atrial enlargement usually without 
significant ventricular dilatation. Thickened myocardium, 
enlarged chambers, intra-cardiac thrombi, valvular leaflets 
and coronary vessels infiltration are other less common 
findings. The extensive deposition in atrial walls results in 
mechanical failure and mechanical standstill [9]. The most 
common manifestation of myocardial dysfunction in cardiac 
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dysfunction. This is mainly due to the direct effect of 
amyloid deposition on myocardial contraction and rel-
axation; a light chain-induced oxidant stress may be also 
involved as well [5]. Systolic dysfunction is the second most 
common presentation, usually when more than 25 % of the 
myocardial mass is replaced by amyloid deposits. Atrial 
dysfunction is mainly related to the impairment of atrial 
emptying due to loss of systolic function and increased after 
load, even in the presence of sinus electric activity. The most 
severe condition is defined as atrial standstill or atrial 
electromechanical dissociation [5]. Sudden death, accounts 
for 30-50 % of all cardiac deaths in systemic amyloidosis, 
usually secondary to ventricular arrhythmias, atrio-ventri-
cular block and acute electromechanical dissociation. Sur-
vival to discharge is low because of recurrent ventricular 
arrhythmias [18]. Prolonged HV interval and late potentials 
may independently predict the risk of sudden cardiac death 
[5]. The data about presence and character of vascular 
abnormalities in cardiac amyloidosis is still limited. Amyloid 
infiltration of small intramural vessels is associated with 
endothelial dysfunction and may explain the anginal chest 
pain in patients with normal coronaries [19]. Modesto et al.,
found in a recent prospective trail involving 59 patients with 
cardiac amyloidosis, an increased carotid artery intimal-
medial thickness (IMT) and lower brachial artery flow-
mediated dilatation (FMD) with an incidence of 88-90% of 
AL patients. However, this finding did not correlate with the 
echocardiographic findings of cardiac amyloidosis [19].  
Clinical Manifestations 
  The restrictive physiology in cardiac amyloidosis results 
in rapid and progressive symptoms and signs including 
mainly progressive dyspnea and chest discomfort. Angina 
due to amyloid deposits in the small and intramyocardial 
coronary arteries is not uncommon. Signs of right sided heart 
failure predominate, with peripheral edema, elevated jugular 
venous pressure with prominent X and Y descent, mitral and 
tricuspid regurgitation murmurs, narrow pulse pressure in the 
setting of restrictive cardiomyopathy. S4 is uncommon and 
is most likely attenuated because of the reduced systolic 
function of the atrial myocardium caused by amyloid 
infiltration. Syncope may be the presenting complaint and is 
usually multifactorial caused by or orthostatism, brady- or 
tachyarrhythmia. Orthostatism results from a decreased 
ventricular filling caused by the underlying restrictive 
pathophysiology. It is not uncommon for pre-existent hyper-
tension to resolve spontaneously as the amyloidosis prog-
resses [4, 5]. Sudden death, a common presentation in 
patients with advanced cardiac amyloidosis, may be caused 
by electromechanical dissociation rather than ventricular 
arrhythmia [5, 4].  
Diagnosis 
  The diagnosis of cardiac amyloidosis requires an evi-
dence of amyloid tissue involvement, usually in abdominal 
fat, rectal mucosa or bone marrow, plus the demonstration of 
an underlying plasma cell clone. Despite the strong evidence 
provided by the finding of amyloid deposits in a biopsy in 
the presence of monoclonal immunoglobulin, it is essential 
to exclude any underlying non-AL amyloidosis associated 
monoclonal gammopahty [11].  
Electrocardiography and Electrophysiologic Studies 
  Pseudoinfarction and low voltage on ECG are the most 
frequent electrocardiographic findings, present in about 47% 
and 46% respectively in patients with biopsy-proven cardiac 
amyloidosis and do not seem to reflect a low ejection 
fraction [14]. Pseudo-infarction pattern with small or absent 
R waves in right precordial leads and less frequently Q 
waves in the inferior leads are not very specific for cardiac 
amyloidosis and occur in the setting of emphysema, 
hypothyroidism, hypoadrenalism, pericardial effusion and 
obesity. The cardiac conduction system is frequently affected 
by amyloid infiltration. His-Purkinje system is the most 
frequently affected parts. Right bundle branch block occurs 
more frequently than left due to its greater susceptibility to 
be affected by the amyloid infiltrates, making it uncommon 
to have an isolated left bundle branch block [4, 20]. H-V 
prolongation > 55 ms may be missed in the setting of a 
narrow QRS. Signal-averaged electrocardiogram may reveal 
delay myocardial activation by showing late potentials 
whose incidence correlates with the echocardiographic 
evidence of cardiac amyloidosis (31% correlation rate versus 
9 % of patients with normal echocardiogram) and the risk of 
sudden cardiac death [4]. Another prognostic electrocardio-
graphic marker may be the presence of reduced heart rate 
variability on 24-h Holter electrocardiogram, being asso-
ciated with an increased short-term mortality [21]. Atrial 
fibrillation and flutter are the most common arrhythmias 
encountered and happen more frequently in patients with 
echocardiographic evidence of increased left ventricular wall 
thickness [14].  
Cardiac Biomarkers 
  Brain Natriuretic Peptide (BNP) expression was found to 
be increased in myocytes adjacent to amyloid deposits. This 
is explained by regional stress effect of amyloid infiltration 
on myocytes and increased filling pressures [22, 23]. In 
cardiac amyloidosis, serum BNP levels are usually high, but 
out of proportion of the degree of heart failure symptoms. 
Serum BNP levels may correlate well with the degree of 
myocardial amyloidal infiltration, but it’s unknown if it 
correlates with the disease’s evolution. It was found that 
even a sub-clinical cardiac amyloid infiltration may produce 
elevated BNP level > 100 pg /ml in 21% of patients without 
echocardiographic evidence of cardiac amyloidosis [22]. 
BNP and N-terminal pro-BNP concentrations are closely 
linked. N-pro-BNP concentration of more than 152 pg/ml 
detected cardiac involvement with a sensitivity and 
specificity of 93% and 90% respectively. Patients with N-
Pro-BNP levels higher than 152 pg/ml also have a higher all 
cause mortality rate (72, 2 % versus 7.6% per year in those 
whose N-Pro-BNP levels were lower than 152 pg/ml) [5]. 
Elevated serum troponin can also be elevated in cardiac amy-
loidosis, due to endothelial dysfunction, microinfarctions and 
small vessels intramural obstruction. Troponin T/ I and N-
terminal-ProBNP levels are of prognostic value in patients 
with amyloidosis and a detection of cardiac troponin I or T 
conferred a median survival of 6 or 8 months (respectively), 
compared with 22 or 21 months, respectively, in those 
without any detectable troponin I/T [24]. Despite the finding 
that NT-proBNP values may decrease rapidly following 
effective chemotherapy and were associated with improved 
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disease progression is not well established yet [9]. Another 
promising newer marker, serum immunoglobulin free light 
chains assay, recently investigated in patients with AL 
amyloidosis, showed a sensitivity which falls between 85 
and 98% [25] and may be used to serially monitor pro-
duction of amyloidogenic light chains during chemotherapy 
[14]. The benefit of using serum markers will be probably 
the greatest in following response to chemotherapy. This 
may require coupling these tools with other reproducible 
quantitative imaging modality like CMR.  
Echocardiographic Findings 
  Echocardiography is an important tool in the diagnosis 
with a broad spectrum of sonographic and hemodynamic 
findings. While it is not diagnostic alone, the specificity of 
the echocardiographic findings increases in the presence of 
the clinical manifestations suggestive of myocardial amy-
loidosis. Diastolic dysfunction, suggested by reduced dias-
tolic mitral inflow velocities upon Tissue Doppler imaging, 
is the earliest finding in cardiac amyloidosis [26, 27, 14]. 
The findings of increased thickness of ventricular walls 
along with a granular sparkling texture of the myocardium 
are strongly suggestive of cardiac amyloid infiltration with a 
specificity approaching 81% [14]. However, this finding is 
present in only about fourth of the patients with amyloid 
cardiac involvement and can be found in other conditions 
like hypertrophic and hypertensive cardiomyopathies. The 
addition of the finding of increased interatrial septal diameter 
remarkably increases the specificity of ventricular wall 
thickness parameter [6, 14]. The thickness of the left 
ventricular walls correlates with reduced survival [9]. 
Similarly, an interventricular septum thickness of more than 
15 mm is also considered a poor prognostic sign [5]. The 
association of increased ventricular thickness with low 
voltage on the electrocardiogram (Low voltage/mass ratio) 
strongly favors the diagnosis of amyloid myocardial infil-
tration [6, 4]. The sensitivity of an index combining a low 
voltage with interventricular septum thickness more than 
1.98 cm, detects amyloidosis with a sensitivity and specifity 
of 72% and 91% respectively [5]. A combined typical 
clinical presentation of cardiac amyloidosis with specific 
echocardiographic findings such as dilated atria, interatrial 
septal hypertrophy > 7 mm, thickened valves and right ven-
tricular free wall may be diagnostic of cardiac amyloidosis 
even without an endomyocardial biopsy [5]. In addition to its 
important role in early detection of diastolic dysfunction, 
Tissue Doppler imaging is very helpful distinguishing amy-
loid or any restrictive cardiomyopathy from constrictive 
pericarditis. The finding of a mitral annular diastolic velocity 
(E’) less than 8 cm/s is suggestive of restrictive rather than 
constrictive physiology [14, 28]. This finding may be the 
result of mitral valve amyloid infiltration causing intrinsic 
atrial dysfunction which is reflected by a diminutive A wave 
with a normal deceleration time [20]. Newer echocardio-
graphic parameters are being developed to facilitate an early 
detection of ventricular dysfunction. Tei index is obtained 
from the tricuspid and pulmonary Doppler flow velocity and 
is defined as ICT + IRT/ ET (ICT = Isovo-lumic Contraction 
Time, IRT = Isovolumic Relaxation Time, and ET= Ejection 
Time). Tei index is usually increased in the cardiac 
amyloidosis and has been shown to be an independent 
prognostic marker [6, 28]. Tissue Doppler Imaging (TDI), 
strain rate imaging and ultrasonic tissue characterization are 
useful in demonstrating the evidence of longitudinal systolic 
dysfunction earlier than any decrease in the left ventricular 
ejection fraction [20].  
Cardiac Catheterization 
  The non-invasive cardiac investigations are usually 
sufficient for the diagnosis of cardiac amyloidosis. The usual 
indication of cardiac catheterization is endomyocardial 
biopsy and hemodynamic assessment that may provide 
important clues for early diagnosis. According to the 
ACC/AHA guidelines [32] and may be of a prognostic value 
by defining the extent of tissue infiltration [4]. Both 
constrictive pericarditis and restrictive cardiomyopathy may 
have similar findings of early rapid diastolic filling and 
elevation with end equalization of diastolic pressures in all 
four cardiac chambers. However, the respiratory changes in 
filling of the left ventricle and right ventricle, as well as the 
enhanced ventricular interaction seen in constrictive peri-
carditis, result in distinctive changes in the left ventricular 
and right ventricular pressures during respiration. These 
abnormalities have been described as discordance (in 
patients with constrictive pericarditis) or concordance (in 
patients with restrictive cardiomyopathy) between the 
pressures in these two chambers, typically seen as reciprocal 
changes in stroke volume, pulse pressure, or peak systolic 
pressure during respiration. The coronary angiogram is 
usually normal because the low incidence of epicardial 
vessels involvement. 
Myocardial Scintigraphy 
  Scintigraphy with technetium-99m pyrophosphate and 
other agents that bind to calcium is often strongly positive 
with prominent amyloid involvement. Although it lacks for 
consistent sensitivity, a positive scans correlate with signi-
ficant cardiac involvement and is not part of the routine 
workup for cardiac amyloidosis. Technetium Tc 99m-3,3-
Diphosphono-1,2-propanodicarboxylic acid scan was recen-
tly suggested to be capable of differentiating TTR-associated 
amyloidosis from AL amyloidosis [9].  
Cardiovascular Magnetic Resonnance in Cardiac 
Amyloidosis 
  Cardiac Magnetic Resonance is a promising non-invasive 
diagnostic tool for cardiac amyloidosis. Its biggest advantage 
so far, is the ability to differentiate amyloidosis from other 
forms of restrictive cardiomyopathy like sarcoidosis and 
lymphoma-related infiltrativedisease or from hypertrophic 
cardiomyopathy. The most characteristic pattern, found in 
approximately two-thirds of patients, is the subendocardial 
late enhancement. This finding may be due to tropism of 
amyloid fibrils for the subendocardium (42%) and less 
frequently to the midwall and subepicardium, with 29% and 
18%, respectively [28]. This technique allows not only 
“mapping” the transmural histological distribution of 
amyloid protein but also estimating the cardiac amyloid load. 
A higher amyloid load and therefore a shorterlongitudinal 
relaxation time correlate with some echocardiographic 
parameters such as LV mass, wall thickness, interatrial septal 
thickness, and diastolic dysfunction [14]. It is expected that 
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future use in screening of early sublinical amyloid infiltra-
tion and treatment response monitoring.  
Management 
  The optimal treatment of immunoglobulin light chain 
amyloidosis (AL) patients requires an (1) early diagnosis, (2) 
an accurate amyloid phenotyping, (3) an effective treatment 
aiming optimally to abolish the source of light chains, induce 
a regression of amyloid deposits and prevent further organ 
damage, and finally (4) maintenance with a supportive 
medical therapy [11, 14]. Since the management and prog-
nosis depends upon types of amyloid fibrils, an accurate 
definition of fibrils type is a critical part of care.  
I - Medical Management 
  The management of heart failure in patients with 
amyloidosis is challenging since it involves the treatment of 
symptoms resulting from a restricitive cardiomyopahty. 
Judicious diuretics use and salt restriction with avoidance of 
intravascular volume depletion remains the mainstay of the 
treatment. High dose are required in the setting of the fre-
quently associated nephrotic syndrome. Angiotensin-conver-
ting enzyme inhibitors and Angiotensin-II receptor blocker 
are poorly tolerated in cardiac amyloidosis associated 
congestive heart failure. This is due to the important role of 
the Angiotensin-II in maintaining the blood pressure and the 
frequently associated autonomic dysfunction precipitating 
orthostatic hypotension if not carefully introduced. The role 
of Calcium channel blockers and digoxin is limited and 
probably detrimental. This is due to an exaggerated negative 
inotropic effect with increased the avidity of amyloid fibrils 
for both molecules. (Just split the sentence). A high 
incidence of sudden death in patients treated with digoxin 
has been reported [6, 20]. A concomitant increase in both 
thromboembolic and bleeding risk is present in patients with 
cardiac amyloidosis [14]. An increased bleeding tendency is 
usually caused by vascular and capillary fragility due 
amyloid infiltration and other associated coagulation abnor-
malities [6]. On the other hand, an underlying hyper-
coagulable state along with an associated dilated cardio-
myopathy increase the thromboembolic risk. Besides atrial 
fibrillation and the evidence of intracardiac thrombi, the 
presence of dysfunctional atrial contractions or a markedly 
dilated atrium caused by extensive amyloid infiltration may 
also be an indication for anticoagulation. This may be 
demonstrated on echocardiography (transthoracic and 
transesophageal) by the presence of a small transmitral A 
wave (< 20 cm/s) with a markedly decreased atrial appen-
dage Doppler velocities (< 40 cm/s) [20]. Patients with 
symptomatic bradyarrhythmias should receive a permanent 
pacemaker implantation. In contrast to AL amyloidosis, 
familial and senile amyloidosis is associated with a higher 
incidence of conduction disturbances. However, the atrial 
and ventricular pacing threshold may be higher than usual in 
some patients.Treatment of ventricular arrhythmia in cardiac 
amyloidosis is not standardized, and the safety of anti-
arrhythmic agents is not well known. The use of devices like 
pacemakers and ICD in cardiac amyloidosis is still not well 
investigated. Deciding to implant an automated implantable 
cardioverter-defibrillator is difficult in these patients due to 
their poor prognosis. The available limited clinical expe-
rience suggests that pacemaker or implantable cardioverter-
defibrillator (ICD) implantation often fails to prevent sudden 
cardiac death. This is due to the high incidence of electro-
mechanical dissociation as a common cause of sudden 
cardiac death in this patient’s population [12]. 
II - Specific Treatments 
Chemotherapy
  Chemotherapy aims to rapidly reduce or abolish the 
supply of the amyloidogenic monoclonal light chain from the 
underlying plasma cell clone, facilitate the regression of 
amyloid deposits and sustain the function of the organs 
involved. This often leads to improved quality of life and 
survival mainly in patients in whom at least 50% reduction 
in monoclonal light chain concentration is achieved [11, 29, 
30]. Cardiac amyloidosis management took advantage of the 
recent validation of circulating free light chain concentration 
(FLC) as a marker of response to chemotherapy [11]. A con-
sensus panel from the International Society for Amyloidosis 
established the criteria for hematological response [11] with 
complete response being defined by a 1) Negative serum and 
urine for monoclonal protein, 2) Normal free light chain 
ratio, and 3) Bone marrow plasma cells < 5%. A partial 
response is defined by the persistence of serum monoclonal 
component > 0.5 g/dl, light chain in the urine with a visible 
peak and >100 mg/day, and free light chain >100 mg/L (At 
least 50% reduction in each parameter). Other experts 
suggest that survival may be better predicted using the 
absolute value of FLC achieved after autologous stem cell 
transplantation (ASCT) rather than the percent reduction of 
FLC [11]. A greater drop in NT-pro-BNP level with 
complete remission also seems to correlate with FLC [11]. 
For AL Amyloidosis, the highest success rate occurs with 
melphalan with a complete hematological remission in 40 % 
of treated patients after one year follow-up [20]. In patients 
with advanced cardiomyopathy, the overall poor prognosis 
and the benefit of the chemotherapy should be balanced with 
a pretreatment mortality risk of more than 30%. An ejection 
fraction of less than 40% is considered a predictor of poor 
outcome and is considered a relative contraindication for 
chemotherapy. Other markers include a markedly elevated 
serum BNP, persistently elevated troponin, and evidence of 
pleural effusion or a significant myocardial thickening [20]. 
The other obstacles encountered in less severe cases consist 
of the poor tolerance of the chemotherapeutic agent or the 
presence of resistant clone [14]. In patients with a predicted 
poor outcome, the use of lower dose of Melphalan-based 
regimens is recommended and better tolerated but response 
is usually delayed [17]. The combination of oral Melphalan 
and high dose Dexamethasone showed remission in 33% of 
patients ineligible for stem cell transplantation [10]. Alterna-
tive regimens for Melphalan-refractory cases, is the combi-
nation of Thalidomide and Dexamethasone [10]. Other drugs 
under investigations include 4’-iodo-4’ Deoxydoxorubicin 
and Interferon- alpha remain under investigation.  
  The treatment of secondary amyloidosis with cardiac 
involvement starts with the treatment of the underlying 
inflammatory or neoplastic process and usually carries a 
poor prognosis. The pharmacological therapy for familial 
amyloidosis is limited, given the production of abnormal 
protein, Transthyretin, by the liver. So, liver transplantation 
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Anti-Inflammatory Drugs are thought to be effective in vitro, 
stabilizing the native protein and preventing the deposition 
of transthyretin amyloid fibrils [10]. Senile cardiac amy-
loidosis treatment is similar to that of congestive heart 
failure, and prognosis is usually favorable.  
Solid Organ Transplantation
  Heart transplantation remains a controversial option 
because of the systemic involvement and the potential recur-
rence of graft amyloidosis [9, 10].  
  In primary amyloidosis, heart transplantation is only a 
palliative procedure and consequent supportive chemo-
therapy should be considered [10]. Long-term prognosis is 
poor (39% survival at 4 years in one study and 30% at 5 
years in another, even with adjuvant chemotherapy [4, 9, 
10]. Sequential heart and autologous stem cell trans-
plantation for primary amyloidosis has been reported [10]. 
Liver transplantation remains the most effective therapy for 
hereditary amyloidosis, by removing mutant TTR proteins.  
Stem Cell Transplantation
  Stem cell transplantation is used exclusively for primary 
amyloidosis. High-dose melphalan followed by ASCT is 
currently considered the most effective therapy for AL 
patients. The number of the potential candidates for this 
combined therapy is usually limited by the strict indications 
in patients with clinically limited cardiac amyloidosis, 
representing only 5% of cases [10, 20]. This combination is 
thought to have a significant survival advantage over oral 
melphalan plus prednisone [11] with a 67% complete hema-
tologic response and a 27% complete organ response in a 
series of 15 patients with an overall survival rate was 75% 
[10]. This applies mainly to highly-selected low-risk 
candidates (age <65 years, normal NT-proBNP and cardiac 
troponins, glomerular filtration rate > 50 mL/min), given the 
high treatment-related mortality, particularly in patients   
with heart failure and multi-organ involvement [11]. Some 
experts proposed criteria for candidates for stem cell 
transplantation. These include, age < 80 years, compensated 
congestive heart failure with ejection fraction > 40%, 
absence of pleural effusions, systolic blood pressure >90 mm 
Hg, and O2 saturation > 95% [4, 10]. This treatment 
modality results in a wide spectrum of complications ranging 
from pneumonia, arrhythmias, gastrointestinal bleeding, 
thromboembolic events, and renal failure to multiorgan 
failure [10].  
The Role of Bortezomib
  Bortezomib is a selective inhibitor of the 26S pro-
teasome, a protein complex involved in the regulation of 
degradation of aberrant proteins as well as for the regulation 
of other proteins involved in the regulation of apoptosis, and 
cell-cycle progression. In an amyloidogenic plasma cell the 
overproduction of misfolded light chains causes a proteo-
toxic stress and other metabolic and red-ox imbalances, 
manifested mainly in the endoplasmic reticulum (ER). 
Therefore, the inhibition of the proteasome by bortezomib 
and blocking NF- B activation exaggerates Enoplasmic 
reticulum stress and promotes apoptosis. Kastritis et al. [31], 
reported 18 cases of AL amyloidosis, among them seven 
patients who failed other therapies, were treated with the   
combination of bortezomib and dexamethasone (BD). This 
study showed a response rate of 94%, a hematological 
complete remission rate of 44% CR and organ response of 
28%. The response time was o short with a median 0.9
months (range, 0.7-1.5) when compared to the 3.5 to 6 
months with other effective treatments. The durability of the 
response to Bortezomib as well as the possible long-term 
side effects and toxicities were not well established, given 
the short follow-up of living patients (median of 11.2 
months). However, a major advantage remains in the 
significantly shorter response time compared with those 
observed in other more aggressive and toxic therapies like 
ASCT where they can be delayed up to 36 months. Further 
clinical trials with long-term follow-up are needed in order 
to investigate and validate the use of Bortezomib in AL 
amyloidosis.  
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